HEALTH AND OCCUPATIONAL EXPOSURE TO ANTI-CANCER DRUGS

本研究的目的是确定是否处理抗- 肿瘤药物或护理接受这些治疗的患者 药物对工作人员的健康构成风险，并评估 工作实践与各种暴露措施之间的关系 这些药物。 具体目的是（1）调查是否有特定的 工作实践与生殖对健康的影响有关， 护士、药剂师和护士助理;（2）评估 工作实践和暴露于毒品之间的关系， 通过工业卫生试验和尿液致突变剂试验;（3） 调查内部和外部暴露措施之间的关系 和临床实验室检查结果，可能反映 exposure. 这项研究是一个竞争性的继续，涉及更多的数据 分析现有的数据集。 受试者是暴露的护士， 处理抗菌塑料的药剂师，护士， 参与成员设施的治疗方案的患者 国家癌症研究所的NSABP项目，包括参与的私人医生诊所 在NSABP临床试验中。 对照组是未暴露的药剂师，护士， 以及来自这些相同设施的助手。 数据分两个阶段收集： 第一阶段是使用自我完成问卷进行调查， 人口统计学和控制变量，暴露。历史，健康， 生殖史 从受试者子样本中采集II期数据 在第一阶段，更新接触和健康史， 暴露可能影响尿液诱变， 阿霉素暴露量测定;临床用血液和尿液样本 实验室测试和尿液诱变，以及暴露日志。

The objectives of this study are to determine whether handling anti- neoplastic drugs or caring for patients receiving treatment with these drugs presents a risk to the health of staff, and to evaluate the relationship between work practices and various measures of exposure to these drugs. The specific aims are (1) to investigate whether specific work practices are associated with reproductive effects on health among nurses, pharmacists and nurses' aides, (2) to evaluate the relationship between work practices and exposure to antineoplastic drugs as measured by an industrial hygiene test and a urine mutagen test and (3) to investigate relationships among internal and external exposure measures and results on clinical laboratory tests which may reflect effects of exposure. The study is a competing continuation involving further data analysis of an existing dataset. Subjects are exposed nurses and pharmacists who handle antineoplastics, and nurses, aides caring for patients on treatment protocols at participating member facilities of the NSABP project of the NCI, including private physician's offices involved in NSABP clinical trials. Controls are unexposed pharmacists, nurses, and aides from these same facilities. Data was gathered in two phases: Phase I was a survey using a self-completion questionnaire covering demographic and control variables, exposure. history, and a health and reproductive history. Phase II collected, from a subsample of subjects in Phase I, updated exposure and health histories, data on other chemical exposures which could affect urine mutagenesis, an industrial hygiene measure of adriamycin exposure; blood and urine samples for clinical laboratory tests and urine mutagenesis, and an exposure log.